United States Adult Vaccine Market Report by Disease wise – Adult Vaccines Market, Disease wise – Numbers of Vaccinated Adults, States and Company Analysis, 2025-2033
Description
United States Adult Vaccine Market Size and Forecast 2025-2033
United States Adult Vaccine Market is expected to reach US$ 11.10 billion by 2033 from US$ 6.55 billion in 2024, with a CAGR of 6.03% from 2025 to 2033. Rising awareness, preventative healthcare activities, changing immunization programs, and the need for cutting-edge vaccines that treat infectious and chronic diseases are all expected to fuel the steady expansion of the US adult vaccine market.
United States Adult Vaccine Industry Overview
By using preventive vaccination to treat both chronic illnesses and infectious diseases, the adult vaccine market in the United States contributes significantly to public health. Growing adult populations and increased awareness of disease prevention continue to fuel demand for vaccines against influenza, shingles, pneumococcal infections, and hepatitis. An aging population and an increase in lifestyle-related disease cases have highlighted the value of adult vaccination, broadening the market's reach. The industry's position has also been strengthened by the availability of cutting-edge vaccinations and the robust support of government immunization programs. Innovation in vaccination formulations, delivery systems, and distribution tactics is being fueled by growing partnerships among pharmaceutical corporations, healthcare providers, and research organizations.
According to data released by the Centers for Disease Control and Prevention in August 2024, for example, influenza affects around 8.8% of individuals in the United States who are between the ages of 18 and 64 annually.
The development of biotechnology and molecular research, which makes it possible to develop next-generation vaccines with improved efficacy and safety profiles, is another important factor. The growing demand for mRNA-based and recombinant vaccines in the US is a result of the quick incorporation of state-of-the-art research into adult vaccination programs. Broader accessibility is also influenced by changing healthcare funding and policy. To address unmet needs across a range of adult age groups, private companies are concurrently making significant investments in growing their product pipelines, clinical trials, and collaborations. These developments aid in the treatment of both infectious diseases and newly developing illnesses for which vaccinations may be useful.
The US adult vaccination market faces obstacles like pricing, supply chain issues, and vaccine reluctance despite its expansion. Public education campaigns, reliable delivery networks, and reasonably priced vaccine access are necessary to address these problems. However, the market for adult vaccines is expected to grow in the future due to the growing importance of preventative healthcare. This market will continue to grow as a result of the convergence of scientific developments, government initiatives, and demographic trends. It is anticipated that the US adult vaccine sector will increase its contribution to bettering health outcomes across the country with more knowledge, innovation, and legislative support.
Key Factors Driving the United States Adult Vaccine Market Growth
Rising Prevalence of Chronic and Infectious Diseases
The growing burden of both chronic and infectious diseases is a major factor propelling the U.S. adult vaccine market. With rising cases of influenza, shingles, hepatitis, and pneumococcal infections, vaccines are increasingly viewed as essential preventive tools. Additionally, chronic conditions such as diabetes and cardiovascular diseases compromise immunity, making adult populations more susceptible to infections. As public awareness about the benefits of vaccines increases, more adults are seeking immunization to safeguard their long-term health. This demand is further supported by healthcare providers who actively recommend adult vaccination as part of preventive care. Pharmaceutical companies are responding by expanding their vaccine portfolios to address multiple diseases, ensuring a steady pipeline of effective solutions. This health-focused trend continues to strengthen the market’s growth trajectory.
Advancements in Biotechnology and Vaccine Innovation
Technological progress in biotechnology has been pivotal in shaping the U.S. adult vaccine market. The development of recombinant, mRNA-based, and adjuvanted vaccines has set new standards for safety, efficacy, and long-lasting protection. These innovations have expanded the scope of immunization beyond traditional infectious diseases to include vaccines under development for conditions like cancer and autoimmune disorders. The rapid success of mRNA vaccines has encouraged pharmaceutical companies to invest in similar technologies for adult immunization. Furthermore, advancements in delivery systems, such as intranasal and needle-free methods, are improving accessibility and patient compliance. Such innovations not only enhance adoption among adults but also drive competitive growth within the market. Continuous R&D investments are expected to expand therapeutic applications, creating long-term opportunities for expansion.
Government Programs and Preventive Healthcare Initiatives
The U.S. government’s strong emphasis on preventive healthcare has been instrumental in driving adult vaccine adoption. Federal and state-level immunization programs, funding support, and awareness campaigns have expanded vaccine accessibility across diverse populations. Public health agencies actively promote adult vaccination as part of routine healthcare, with a focus on protecting vulnerable groups, including the elderly and immunocompromised individuals. Partnerships between government agencies, healthcare providers, and private players have also enabled smoother distribution and outreach. Preventive healthcare initiatives, supported by insurance coverage for many vaccines, further encourage uptake. By integrating adult vaccination into broader healthcare policies, the government continues to create a favorable environment for the market. These efforts ensure not only public safety but also long-term cost savings in healthcare expenditure.
Challenges in the United States Adult Vaccine Market
Vaccine Hesitancy and Misinformation
One of the persistent challenges in the U.S. adult vaccine market is vaccine hesitancy, often fueled by misinformation, misconceptions about side effects, and distrust of pharmaceutical companies. Despite proven safety and efficacy, a segment of the adult population remains reluctant to receive vaccinations, which hampers overall coverage rates. Social media and misinformation campaigns amplify skepticism, creating hurdles for public health authorities and healthcare providers. Overcoming hesitancy requires targeted educational initiatives, transparent communication, and community engagement to rebuild trust. While efforts are underway to combat misinformation, vaccine hesitancy remains a barrier that slows adoption, reduces market penetration, and impacts the broader effectiveness of immunization programs across adult populations.
High Costs and Access Barriers
The cost of adult vaccines and challenges in accessibility represent another significant market obstacle. While certain vaccines are covered by insurance, out-of-pocket expenses can deter many individuals, particularly in low-income groups. Additionally, disparities in healthcare infrastructure between urban and rural areas limit vaccine availability and distribution. This unequal access prevents widespread adoption, even when awareness is high. Supply chain complexities, particularly during peak demand seasons, also affect timely availability. Addressing these barriers requires coordinated efforts between public and private stakeholders to reduce costs, strengthen infrastructure, and improve affordability. Without targeted strategies to expand equitable access, these challenges may continue to hinder full market growth and coverage across the United States.
United States Adult Vaccine Market Overview by States
The U.S. adult vaccine market shows strong regional presence, with California, Texas, New York, and Florida leading adoption, driven by large populations, advanced healthcare infrastructure, and state-level support for preventive immunization programs. The following provides a market overview by States:
California Adult Vaccine Market
California represents a significant share of the U.S. adult vaccine market, supported by its large, diverse population and advanced healthcare infrastructure. The state’s emphasis on preventive healthcare and wellness has encouraged widespread adoption of adult immunization programs. Public health initiatives and state-level policies have expanded vaccine access, particularly among vulnerable and aging populations. California’s role as a hub for biotechnology and pharmaceutical innovation further supports the development and distribution of advanced vaccines. Healthcare providers, clinics, and pharmacies across urban and rural areas are actively engaged in promoting adult vaccination, ensuring broader coverage. With strong awareness campaigns and active participation from private and public stakeholders, California continues to be a key driver of adult vaccine adoption in the United States.
Texas Adult Vaccine Market
Texas is an important contributor to the U.S. adult vaccine market, fueled by its large population and evolving healthcare infrastructure. The state has been proactive in expanding preventive healthcare measures, including adult immunization campaigns. Growing awareness about influenza, shingles, and pneumococcal vaccines has led to rising demand across urban and semi-urban centers. Texas also benefits from strong participation by healthcare providers, pharmacies, and state agencies that actively promote vaccination programs. Its diverse demographic profile, including an aging population and individuals with chronic conditions, further underpins demand. While challenges remain in terms of accessibility in rural areas, state-level initiatives and insurance support are improving vaccine adoption. Texas continues to strengthen its position as a vital regional market for adult immunization in the U.S.
New York Adult Vaccine Market
New York has established itself as a dynamic market for adult vaccines, driven by its advanced healthcare system and strong focus on public health. The state’s dense and diverse population supports high demand for a wide range of vaccines, including influenza, hepatitis, and shingles. Government-backed immunization programs and awareness initiatives play a central role in encouraging vaccine uptake among adults, particularly vulnerable populations. The state’s leading research institutions and biotechnology companies also contribute to ongoing innovation and availability of advanced vaccines. Healthcare providers, clinics, and pharmacies in both urban and suburban areas ensure broad distribution, making vaccines accessible to a majority of residents. With strong preventive healthcare initiatives and active participation from private and public sectors, New York remains a leading hub for adult vaccine adoption.
Florida Adult Vaccine Market
Florida is a fast-growing market for adult vaccines, driven largely by its sizable elderly population and heightened focus on preventive healthcare. The state records strong demand for vaccines against influenza, pneumococcal infections, and shingles, which are critical for aging demographics. Public health programs and partnerships with healthcare providers have expanded vaccine awareness and accessibility across urban centers and rural regions. Florida’s diverse population and active retirement communities further underscore the importance of adult vaccination programs. Pharmacies, clinics, and healthcare institutions play a pivotal role in ensuring vaccine distribution and education. With ongoing support from government policies and private stakeholders, Florida continues to be an essential regional market contributing to the broader adoption of adult vaccines across the United States.
Recent Developments in U.S. Adult Vaccine Market
• The FDA approved Moderna, Inc.'s mNEXSPIKE COVID-19 vaccine in May 2025 for use in treating people aged 12 to 64 in the United States.
Market Segmentations
Disease wise – Adult Vaccines Market
• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR (Measles, Mumps, and Rubella Vaccine)
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Travel and Miscellaneous
• Varicella
Disease wise – Numbers of Vaccinated Adults
• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Varicella
States
• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States
All the Key players have been covered
• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis
Company Analysis:
• GlaxoSmithKline, plc.’s Vaccines Sales
• AstraZeneca plc Vaccines Sales
• Sanofi Pasteur’s Vaccines Sales
• Pfizer, Inc.’s Vaccines Sales
• CSL Limited sales
United States Adult Vaccine Market is expected to reach US$ 11.10 billion by 2033 from US$ 6.55 billion in 2024, with a CAGR of 6.03% from 2025 to 2033. Rising awareness, preventative healthcare activities, changing immunization programs, and the need for cutting-edge vaccines that treat infectious and chronic diseases are all expected to fuel the steady expansion of the US adult vaccine market.
United States Adult Vaccine Industry Overview
By using preventive vaccination to treat both chronic illnesses and infectious diseases, the adult vaccine market in the United States contributes significantly to public health. Growing adult populations and increased awareness of disease prevention continue to fuel demand for vaccines against influenza, shingles, pneumococcal infections, and hepatitis. An aging population and an increase in lifestyle-related disease cases have highlighted the value of adult vaccination, broadening the market's reach. The industry's position has also been strengthened by the availability of cutting-edge vaccinations and the robust support of government immunization programs. Innovation in vaccination formulations, delivery systems, and distribution tactics is being fueled by growing partnerships among pharmaceutical corporations, healthcare providers, and research organizations.
According to data released by the Centers for Disease Control and Prevention in August 2024, for example, influenza affects around 8.8% of individuals in the United States who are between the ages of 18 and 64 annually.
The development of biotechnology and molecular research, which makes it possible to develop next-generation vaccines with improved efficacy and safety profiles, is another important factor. The growing demand for mRNA-based and recombinant vaccines in the US is a result of the quick incorporation of state-of-the-art research into adult vaccination programs. Broader accessibility is also influenced by changing healthcare funding and policy. To address unmet needs across a range of adult age groups, private companies are concurrently making significant investments in growing their product pipelines, clinical trials, and collaborations. These developments aid in the treatment of both infectious diseases and newly developing illnesses for which vaccinations may be useful.
The US adult vaccination market faces obstacles like pricing, supply chain issues, and vaccine reluctance despite its expansion. Public education campaigns, reliable delivery networks, and reasonably priced vaccine access are necessary to address these problems. However, the market for adult vaccines is expected to grow in the future due to the growing importance of preventative healthcare. This market will continue to grow as a result of the convergence of scientific developments, government initiatives, and demographic trends. It is anticipated that the US adult vaccine sector will increase its contribution to bettering health outcomes across the country with more knowledge, innovation, and legislative support.
Key Factors Driving the United States Adult Vaccine Market Growth
Rising Prevalence of Chronic and Infectious Diseases
The growing burden of both chronic and infectious diseases is a major factor propelling the U.S. adult vaccine market. With rising cases of influenza, shingles, hepatitis, and pneumococcal infections, vaccines are increasingly viewed as essential preventive tools. Additionally, chronic conditions such as diabetes and cardiovascular diseases compromise immunity, making adult populations more susceptible to infections. As public awareness about the benefits of vaccines increases, more adults are seeking immunization to safeguard their long-term health. This demand is further supported by healthcare providers who actively recommend adult vaccination as part of preventive care. Pharmaceutical companies are responding by expanding their vaccine portfolios to address multiple diseases, ensuring a steady pipeline of effective solutions. This health-focused trend continues to strengthen the market’s growth trajectory.
Advancements in Biotechnology and Vaccine Innovation
Technological progress in biotechnology has been pivotal in shaping the U.S. adult vaccine market. The development of recombinant, mRNA-based, and adjuvanted vaccines has set new standards for safety, efficacy, and long-lasting protection. These innovations have expanded the scope of immunization beyond traditional infectious diseases to include vaccines under development for conditions like cancer and autoimmune disorders. The rapid success of mRNA vaccines has encouraged pharmaceutical companies to invest in similar technologies for adult immunization. Furthermore, advancements in delivery systems, such as intranasal and needle-free methods, are improving accessibility and patient compliance. Such innovations not only enhance adoption among adults but also drive competitive growth within the market. Continuous R&D investments are expected to expand therapeutic applications, creating long-term opportunities for expansion.
Government Programs and Preventive Healthcare Initiatives
The U.S. government’s strong emphasis on preventive healthcare has been instrumental in driving adult vaccine adoption. Federal and state-level immunization programs, funding support, and awareness campaigns have expanded vaccine accessibility across diverse populations. Public health agencies actively promote adult vaccination as part of routine healthcare, with a focus on protecting vulnerable groups, including the elderly and immunocompromised individuals. Partnerships between government agencies, healthcare providers, and private players have also enabled smoother distribution and outreach. Preventive healthcare initiatives, supported by insurance coverage for many vaccines, further encourage uptake. By integrating adult vaccination into broader healthcare policies, the government continues to create a favorable environment for the market. These efforts ensure not only public safety but also long-term cost savings in healthcare expenditure.
Challenges in the United States Adult Vaccine Market
Vaccine Hesitancy and Misinformation
One of the persistent challenges in the U.S. adult vaccine market is vaccine hesitancy, often fueled by misinformation, misconceptions about side effects, and distrust of pharmaceutical companies. Despite proven safety and efficacy, a segment of the adult population remains reluctant to receive vaccinations, which hampers overall coverage rates. Social media and misinformation campaigns amplify skepticism, creating hurdles for public health authorities and healthcare providers. Overcoming hesitancy requires targeted educational initiatives, transparent communication, and community engagement to rebuild trust. While efforts are underway to combat misinformation, vaccine hesitancy remains a barrier that slows adoption, reduces market penetration, and impacts the broader effectiveness of immunization programs across adult populations.
High Costs and Access Barriers
The cost of adult vaccines and challenges in accessibility represent another significant market obstacle. While certain vaccines are covered by insurance, out-of-pocket expenses can deter many individuals, particularly in low-income groups. Additionally, disparities in healthcare infrastructure between urban and rural areas limit vaccine availability and distribution. This unequal access prevents widespread adoption, even when awareness is high. Supply chain complexities, particularly during peak demand seasons, also affect timely availability. Addressing these barriers requires coordinated efforts between public and private stakeholders to reduce costs, strengthen infrastructure, and improve affordability. Without targeted strategies to expand equitable access, these challenges may continue to hinder full market growth and coverage across the United States.
United States Adult Vaccine Market Overview by States
The U.S. adult vaccine market shows strong regional presence, with California, Texas, New York, and Florida leading adoption, driven by large populations, advanced healthcare infrastructure, and state-level support for preventive immunization programs. The following provides a market overview by States:
California Adult Vaccine Market
California represents a significant share of the U.S. adult vaccine market, supported by its large, diverse population and advanced healthcare infrastructure. The state’s emphasis on preventive healthcare and wellness has encouraged widespread adoption of adult immunization programs. Public health initiatives and state-level policies have expanded vaccine access, particularly among vulnerable and aging populations. California’s role as a hub for biotechnology and pharmaceutical innovation further supports the development and distribution of advanced vaccines. Healthcare providers, clinics, and pharmacies across urban and rural areas are actively engaged in promoting adult vaccination, ensuring broader coverage. With strong awareness campaigns and active participation from private and public stakeholders, California continues to be a key driver of adult vaccine adoption in the United States.
Texas Adult Vaccine Market
Texas is an important contributor to the U.S. adult vaccine market, fueled by its large population and evolving healthcare infrastructure. The state has been proactive in expanding preventive healthcare measures, including adult immunization campaigns. Growing awareness about influenza, shingles, and pneumococcal vaccines has led to rising demand across urban and semi-urban centers. Texas also benefits from strong participation by healthcare providers, pharmacies, and state agencies that actively promote vaccination programs. Its diverse demographic profile, including an aging population and individuals with chronic conditions, further underpins demand. While challenges remain in terms of accessibility in rural areas, state-level initiatives and insurance support are improving vaccine adoption. Texas continues to strengthen its position as a vital regional market for adult immunization in the U.S.
New York Adult Vaccine Market
New York has established itself as a dynamic market for adult vaccines, driven by its advanced healthcare system and strong focus on public health. The state’s dense and diverse population supports high demand for a wide range of vaccines, including influenza, hepatitis, and shingles. Government-backed immunization programs and awareness initiatives play a central role in encouraging vaccine uptake among adults, particularly vulnerable populations. The state’s leading research institutions and biotechnology companies also contribute to ongoing innovation and availability of advanced vaccines. Healthcare providers, clinics, and pharmacies in both urban and suburban areas ensure broad distribution, making vaccines accessible to a majority of residents. With strong preventive healthcare initiatives and active participation from private and public sectors, New York remains a leading hub for adult vaccine adoption.
Florida Adult Vaccine Market
Florida is a fast-growing market for adult vaccines, driven largely by its sizable elderly population and heightened focus on preventive healthcare. The state records strong demand for vaccines against influenza, pneumococcal infections, and shingles, which are critical for aging demographics. Public health programs and partnerships with healthcare providers have expanded vaccine awareness and accessibility across urban centers and rural regions. Florida’s diverse population and active retirement communities further underscore the importance of adult vaccination programs. Pharmacies, clinics, and healthcare institutions play a pivotal role in ensuring vaccine distribution and education. With ongoing support from government policies and private stakeholders, Florida continues to be an essential regional market contributing to the broader adoption of adult vaccines across the United States.
Recent Developments in U.S. Adult Vaccine Market
• The FDA approved Moderna, Inc.'s mNEXSPIKE COVID-19 vaccine in May 2025 for use in treating people aged 12 to 64 in the United States.
Market Segmentations
Disease wise – Adult Vaccines Market
• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR (Measles, Mumps, and Rubella Vaccine)
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Travel and Miscellaneous
• Varicella
Disease wise – Numbers of Vaccinated Adults
• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Varicella
States
• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States
All the Key players have been covered
• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis
Company Analysis:
• GlaxoSmithKline, plc.’s Vaccines Sales
• AstraZeneca plc Vaccines Sales
• Sanofi Pasteur’s Vaccines Sales
• Pfizer, Inc.’s Vaccines Sales
• CSL Limited sales
Table of Contents
200 Pages
- 1. Introduction
- 2. Research & Methodology
- 2.1 Data Source
- 2.1.1 Primary Sources
- 2.1.2 Secondary Sources
- 2.2 Research Approach
- 2.2.1 Top-Down Approach
- 2.2.2 Bottom-Up Approach
- 2.3 Forecast Projection Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. United States Adult Vaccine Market
- 5.1 Historical Market Trends
- 5.2 Market Forecast
- 6. Adult Vaccines Market & Numbers Share Analysis
- 6.1 By Adult Vaccine Market Share
- 6.2 By States Adult Vaccine Market Share
- 6.3 By Adult Vaccinated Population Share
- 7. Disease wise – Adult Vaccines Market
- 7.1 Influenza
- 7.1.1 Market Analysis
- 7.1.2 Market Size & Forecast
- 7.2 Cervical Cancer (HPV)
- 7.2.1 Market Analysis
- 7.2.2 Market Size & Forecast
- 7.3 Zoster (Shingles)
- 7.3.1 Market Analysis
- 7.3.2 Market Size & Forecast
- 7.4 MMR (Measles, Mumps, and Rubella Vaccine)
- 7.4.1 Market Analysis
- 7.4.2 Market Size & Forecast
- 7.5 Pneumococcal
- 7.5.1 Market Analysis
- 7.5.2 Market Size & Forecast
- 7.6 Meningococcal
- 7.6.1 Market Analysis
- 7.6.2 Market Size & Forecast
- 7.7 Hepatitis
- 7.7.1 Market Analysis
- 7.7.2 Market Size & Forecast
- 7.8 TdaP
- 7.8.1 Market Analysis
- 7.8.2 Market Size & Forecast
- 7.9 Travel and Miscellaneous
- 7.9.1 Market Analysis
- 7.9.2 Market Size & Forecast
- 7.10 Varicella
- 7.10.1 Market Analysis
- 7.10.2 Market Size & Forecast
- 8. Disease wise – Numbers of Vaccinated Adults
- 8.1 Influenza
- 8.1.1 Number Analysis
- 8.1.2 Number Size & Forecast
- 8.2 Cervical Cancer (HPV)
- 8.2.1 Number Analysis
- 8.2.2 Number Size & Forecast
- 8.3 Zoster (Shingles)
- 8.3.1 Number Analysis
- 8.3.2 Number Size & Forecast
- 8.4 MMR
- 8.4.1 Number Analysis
- 8.4.2 Number Size & Forecast
- 8.5 Pneumococcal
- 8.5.1 Number Analysis
- 8.5.2 Number Size & Forecast
- 8.6 Meningococcal
- 8.6.1 Number Analysis
- 8.6.2 Number Size & Forecast
- 8.7 Hepatitis
- 8.7.1 Number Analysis
- 8.7.2 Number Size & Forecast
- 8.8 TdaP
- 8.8.1 Number Analysis
- 8.8.2 Number Size & Forecast
- 8.9 Varicella
- 8.9.1 Number Analysis
- 8.9.2 Number Size & Forecast
- 9. Top States
- 9.1 California
- 9.1.1 Market Analysis
- 9.1.2 Market Size & Forecast
- 9.2 Texas
- 9.2.1 Market Analysis
- 9.2.2 Market Size & Forecast
- 9.3 New York
- 9.3.1 Market Analysis
- 9.3.2 Market Size & Forecast
- 9.4 Florida
- 9.4.1 Market Analysis
- 9.4.2 Market Size & Forecast
- 9.5 Illinois
- 9.5.1 Market Analysis
- 9.5.2 Market Size & Forecast
- 9.6 Pennsylvania
- 9.6.1 Market Analysis
- 9.6.2 Market Size & Forecast
- 9.7 Ohio
- 9.7.1 Market Analysis
- 9.7.2 Market Size & Forecast
- 9.8 Georgia
- 9.8.1 Market Analysis
- 9.8.2 Market Size & Forecast
- 9.9 New Jersey
- 9.9.1 Market Analysis
- 9.9.2 Market Size & Forecast
- 9.10 Washington
- 9.10.1 Market Analysis
- 9.10.2 Market Size & Forecast
- 9.11 North Carolina
- 9.11.1 Market Analysis
- 9.11.2 Market Size & Forecast
- 9.12 Massachusetts
- 9.12.1 Market Analysis
- 9.12.2 Market Size & Forecast
- 9.13 Virginia
- 9.13.1 Market Analysis
- 9.13.2 Market Size & Forecast
- 9.14 Michigan
- 9.14.1 Market Analysis
- 9.14.2 Market Size & Forecast
- 9.15 Maryland
- 9.15.1 Market Analysis
- 9.15.2 Market Size & Forecast
- 9.16 Colorado
- 9.16.1 Market Analysis
- 9.16.2 Market Size & Forecast
- 9.17 Tennessee
- 9.17.1 Market Analysis
- 9.17.2 Market Size & Forecast
- 9.18 Indiana
- 9.18.1 Market Analysis
- 9.18.2 Market Size & Forecast
- 9.19 Arizona
- 9.19.1 Market Analysis
- 9.19.2 Market Size & Forecast
- 9.20 Minnesota
- 9.20.1 Market Analysis
- 9.20.2 Market Size & Forecast
- 9.21 Wisconsin
- 9.21.1 Market Analysis
- 9.21.2 Market Size & Forecast
- 9.22 Missouri
- 9.22.1 Market Analysis
- 9.22.2 Market Size & Forecast
- 9.23 Connecticut
- 9.23.1 Market Analysis
- 9.23.2 Market Size & Forecast
- 9.24 South Carolina
- 9.24.1 Market Analysis
- 9.24.2 Market Size & Forecast
- 9.25 Oregon
- 9.25.1 Market Analysis
- 9.25.2 Market Size & Forecast
- 9.26 Louisiana
- 9.26.1 Market Analysis
- 9.26.2 Market Size & Forecast
- 9.27 Alabama
- 9.27.1 Market Analysis
- 9.27.2 Market Size & Forecast
- 9.28 Kentucky
- 9.28.1 Market Analysis
- 9.28.2 Market Size & Forecast
- 9.29 Rest of United States
- 9.29.1 Market Analysis
- 9.29.2 Market Size & Forecast
- 10. Mergers and Acquisitions in the Vaccine Industry
- 11. Vaccines and Regulator’s Interventions
- 11.1 Making and Meeting Standards of Quality and Safety
- 11.2 Vaccine Funding
- 12. Vaccines – Products and Pipeline
- 13. Value Chain Analysis
- 14. Porter's Five Forces Analysis
- 14.1 Bargaining Power of Buyers
- 14.2 Bargaining Power of Suppliers
- 14.3 Degree of Competition
- 14.4 Threat of New Entrants
- 14.5 Threat of Substitutes
- 15. SWOT Analysis
- 15.1 Strength
- 15.2 Weakness
- 15.3 Opportunity
- 15.4 Threats
- 16. Pricing Benchmark Analysis
- 16.1 GlaxoSmithKline, plc.’s Vaccines Sales
- 16.2 AstraZeneca plc Vaccines Sales
- 16.3 Sanofi Pasteur’s Vaccines Sales
- 16.4 Pfizer, Inc.’s Vaccines Sales
- 16.5 CSL Limited sales
- 17. Key Players Analysis
- 17.1 GlaxoSmithKline, plc.’s Vaccines Sales
- 17.1.1 Overviews
- 17.1.2 Key Person
- 17.1.3 Recent Developments
- 17.1.4 SWOT Analysis
- 17.1.5 Revenue Analysis
- 17.2 AstraZeneca plc Vaccines Sales
- 17.2.1 Overviews
- 17.2.2 Key Person
- 17.2.3 Recent Developments
- 17.2.4 SWOT Analysis
- 17.2.5 Revenue Analysis
- 17.3 Sanofi Pasteur’s Vaccines Sales
- 17.3.1 Overviews
- 17.3.2 Key Person
- 17.3.3 Recent Developments
- 17.3.4 SWOT Analysis
- 17.3.5 Revenue Analysis
- 17.4 Pfizer, Inc.’s Vaccines Sales
- 17.4.1 Overviews
- 17.4.2 Key Person
- 17.4.3 Recent Developments
- 17.4.4 SWOT Analysis
- 17.4.5 Revenue Analysis
- 17.5 CSL Limited sales
- 17.5.1 Overviews
- 17.5.2 Key Person
- 17.5.3 Recent Developments
- 17.5.4 SWOT Analysis
- 17.5.5 Revenue Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.